TBPH
Theravance Biopharma Inc
$10.58
Earnings Summary
Revenue | $12.84Mn |
Net Profits | $-59.43Mn |
Net Profit Margins | -462.95% |
Highlights
Theravance Biopharma Inc’s revenue jumped 200.3% since last year same period to $12.84Mn in the Q3 2018. On a quarterly growth basis, Theravance Biopharma Inc has generated -45.31% fall in its revenue since last 3-months.
Theravance Biopharma Inc’s net profit jumped 11.13% since last year same period to $-59.43Mn in the Q3 2018. On a quarterly growth basis, Theravance Biopharma Inc has generated -45.6% fall in its net profits since last 3-months.
Theravance Biopharma Inc’s net profit margin jumped 70.41% since last year same period to -462.95% in the Q3 2018. On a quarterly growth basis, Theravance Biopharma Inc has generated -166.26% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Theravance Biopharma Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Current Year | -0.09 |
Highlights
Theravance Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.09 - a 50% jump from last quarter’s estimates.
Theravance Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.09.
Key Ratios
Key ratios of the Theravance Biopharma Inc post its Q4 2022 earnings
Return on Assets (ROA) | -0.1 |
Return on Equity (ROE) | -1.8 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Theravance Biopharma Inc’s return on assets (ROA) stands at -0.1.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Theravance Biopharma Inc’s return on equity (ROE) stands at -1.8.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-05-09 | -1.26 | -1.22 | 3.17% |
2018-08-02 | -1.2 | -0.76 | 36.67% |
2018-11-08 | -1.15 | -1.1 | 4.35% |
2019-02-28 | -1.06 | -0.92 | 13.21% |
Company Information
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Its research is focused in the areas of inflammation and immunology.
Organisation | Theravance Biopharma Inc |
Headquarters | Ugland House, George Town, Cayman Islands, KY1-1104 |
Employees | 111 |
Industry | Health Technology |
CEO | Rick Winningham |
